155 related articles for article (PubMed ID: 27925044)
21. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.
Lee HS; Park LC; Lee EM; Lee SJ; Shin SH; Im H; Do KM; Kim EJ; Ye BJ; Song MK; Kim SH; Lee SM; Lee WS; Kim YS
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):70-5. PubMed ID: 22088920
[TBL] [Abstract][Full Text] [Related]
22. Prediction of major bleeding events in 1381 patients with essential thrombocythemia.
Stuckey R; Ianotto JC; Santoro M; Czyż A; Encinas MMP; Gómez-Casares MT; Pereira MSN; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Sobas MA
Int J Hematol; 2023 Nov; 118(5):589-595. PubMed ID: 37660316
[TBL] [Abstract][Full Text] [Related]
23. Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study.
Stuckey R; Ianotto JC; Santoro M; Czyż A; Perez Encinas MM; Gómez-Casares MT; Noya Pereira MS; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Wróbel T; Sobas MA
Br J Haematol; 2022 Oct; 199(1):86-94. PubMed ID: 35906782
[TBL] [Abstract][Full Text] [Related]
24. Leukocytosis and risk stratification assessment in essential thrombocythemia.
Carobbio A; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Finazzi G; Rambaldi A; Barbui T
J Clin Oncol; 2008 Jun; 26(16):2732-6. PubMed ID: 18443353
[TBL] [Abstract][Full Text] [Related]
25. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
[TBL] [Abstract][Full Text] [Related]
26. DETERMINING THE RISK OF THROMBOSIS AMONG THE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA.
Ghirdaladze D; Vatsadze T; Kirtava T
Georgian Med News; 2020 Feb; (299):143-146. PubMed ID: 32242862
[TBL] [Abstract][Full Text] [Related]
27. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
28. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Vannucchi AM; Antonioli E; Gisslinger H; Buxhofer-Ausch V; Finazzi G; Gangat N; Tefferi A; Barbui T
Blood; 2011 Jun; 117(22):5857-9. PubMed ID: 21490340
[TBL] [Abstract][Full Text] [Related]
30. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
31. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.
Carobbio A; Finazzi G; Guerini V; Spinelli O; Delaini F; Marchioli R; Borrelli G; Rambaldi A; Barbui T
Blood; 2007 Mar; 109(6):2310-3. PubMed ID: 17110452
[TBL] [Abstract][Full Text] [Related]
32. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
33. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.
Palandri F; Polverelli N; Catani L; Ottaviani E; Baccarani M; Vianelli N
Ann Hematol; 2011 Aug; 90(8):933-8. PubMed ID: 21287350
[TBL] [Abstract][Full Text] [Related]
34. Predictors of survival and cause of death in patients with essential thrombocythemia.
Lekovic D; Gotic M; Sefer D; Mitrovic-Ajtic O; Cokic V; Milic N
Eur J Haematol; 2015 Nov; 95(5):461-6. PubMed ID: 25645731
[TBL] [Abstract][Full Text] [Related]
35. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
Passamonti F; Thiele J; Girodon F; Rumi E; Carobbio A; Gisslinger H; Kvasnicka HM; Ruggeri M; Randi ML; Gangat N; Vannucchi AM; Gianatti A; Gisslinger B; Müllauer L; Rodeghiero F; d'Amore ES; Bertozzi I; Hanson CA; Boveri E; Marino F; Maffioli M; Caramazza D; Antonioli E; Carrai V; Buxhofer-Ausch V; Pascutto C; Cazzola M; Barbui T; Tefferi A
Blood; 2012 Aug; 120(6):1197-201. PubMed ID: 22740446
[TBL] [Abstract][Full Text] [Related]
36. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.
Alvarez-Larrán A; Cuevas B; Velez P; Noya S; Caballero-Navarro G; Ferrer-Marín F; Carbonell S; Pérez-Encinas M; Gómez-Casares MT; Pérez-López R; Magro E; Moretó A; Pastor-Galán I; Angona A; Mata-Vázquez MI; Guerrero-Fernández L; Guerra JM; Carreño-Tarragona G; Fox L; Murillo I; García-Gutiérrez V; Mora E; Stuckey R; Arellano-Rodrigo E; Hernández-Boluda JC; Pereira A
Hemasphere; 2023 Aug; 7(8):e936. PubMed ID: 37476303
[TBL] [Abstract][Full Text] [Related]
37. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan.
Baba T; Hashimoto Y; Yasuda H; Araki M; Edahiro Y; Morishita S; Ochiai T; Shirane S; Ando J; Komatsu N
Hematology; 2022 Dec; 27(1):157-166. PubMed ID: 35068369
[TBL] [Abstract][Full Text] [Related]
38. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Andriani A; Latagliata R; Anaclerico B; Spadea A; Rago A; Di Veroli A; Spirito F; Porrini R; De Muro M; Crescenzi Leonetti S; Villivà N; De Gregoris C; Montefusco E; Polverelli N; Santoro C; Breccia M; Cimino G; Majolino I; Mazzucconi MG; Vianelli N; Alimena G; Montanaro M; Palandri F
Am J Hematol; 2016 Mar; 91(3):318-21. PubMed ID: 26748894
[TBL] [Abstract][Full Text] [Related]
39. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
Pérez Encinas MM; Sobas M; Gómez-Casares MT; Abuin Blanco A; Noya Pereira MS; Raya JM; Andrade-Campos MM; Álvarez Larrán A; Lewandowski K; Łukasz S; Hernández Boluda JC; Ferrer-Marín F; Fox ML; Gołos A; Gasior Kabat M; Magro Mazo E; Czyż A; Martín Martín A; Bellosillo Paricio B; Quinteiro García C; González Martín JM; Stuckey R
Eur J Haematol; 2021 Mar; 106(3):371-379. PubMed ID: 33275803
[TBL] [Abstract][Full Text] [Related]
40. Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.
Zhou D; Chen W; Cheng H; Qiao JL; Zhu LL; Li ZY; Xu KL
Leuk Res; 2018 Jun; 69():1-6. PubMed ID: 29609040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
